Table 3.
Mean (± standard deviation) intraocular pressure (mmHg) at each visit and time point in the travoprost arms of the seven studies included in this integrated analysis (per protocol data set)
| Reference | Baseline | Week 2 | Week 12 | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| 0800 | 1000 | 1600 | 0800 | 1000 | 1600 | 0800 | 1000 | 1600 | |
| Netland et al29 | 26.8 (2.6) | 25.2 (2.8) | 24.6 (2.8) | 18.8 (3.6) | 17.52 (3.5) | 17.3 (3.0) | 18.7 (3.3) | 17.3 (3.7) | 17.6 (3.1) |
| Gross et al27 | |||||||||
| Travoprost | 27.1 (2.9) | – | – | 18.5 (4.0) | – | – | – | – | – |
| Travoprost with sofZia® | 26.9 (3.2) | – | – | 18.7 (4.2) | – | – | – | – | – |
| Lewis et al28 | |||||||||
| Travoprost | 27.2 (2.7) | 25.6 (2.9) | 24.9 (2.9) | 18.8 (3.5) | 17.9 (3.6) | 17.5 (3.5) | 18.8 (3.6) | 17.7 (3.3) | 17.2 (3.1) |
| Travoprost with sofZia® | 27.0 (2.3) | 25.5 (2.7) | 24.8 (2.7) | 18.5 (2.9) | 17.7 (3.3) | 17.3 (3.1) | 18.7 (3.5) | 17.7 (3.2) | 17.3 (3.2) |
| Goldberg et al26 | 27.4 (2.8) | 26.5 (2.9) | 25.6 (3.0) | 18.9 (3.4) | 17.9 (3.3) | 17.4 (3.3) | 18.5 (3.4) | 17.6 (3.1) | 16.8 (2.9) |
| Barnebey et al23 | 29.8 (2.7) | 28.2 (3.1) | 26.9 (3.5) | 20.6 (3.9) | 19.0 (3.8) | 18.6 (3.6) | 20.6 (3.7) | 19.2 (3.2) | 18.7 (3.2) |
| Fellman et al24 | 27.3 (3.0) | 25.7 (3.4) | 25.1 (3.0) | 19.3 (3.7) | 18.1 (3.4) | 17.6 (3.2) | 19.7 (3.9) | 18.5 (3.8) | 18.0 (3.3) |
| Gandolfi et al25 | 26.9 (2.6) | 25.6 (2.9) | 24.8 (2.8) | 18.1 (3.5) | 17.8 (3.5) | 17.1 (3.2) | 18.0 (3.5) | 17.4 (3.4) | 17.0 (3.7) |
Note: All studies evaluated travoprost (preserved with benzalkonium chloride) unless otherwise stated.